ranibizumab

As nouns the difference between terms and ranibizumab

is that terms is while ranibizumab is a monoclonal antibody fragment derived from the same parent murine antibody as bevacizumab, used as an antiangiogenic.

As nouns the difference between antiangiogenic and ranibizumab

is that antiangiogenic is any drug of this kind while ranibizumab is a monoclonal antibody fragment derived from the same parent murine antibody as bevacizumab, used as an antiangiogenic.

As an adjective antiangiogenic

is that inhibits angiogenesis (especially when used to combat cancer).

As nouns the difference between bevacizumab and ranibizumab

is that bevacizumab is a monoclonal antibody used in the treatment of cancer while ranibizumab is a monoclonal antibody fragment derived from the same parent murine antibody as bevacizumab, used as an antiangiogenic.

As nouns the difference between antibody and ranibizumab

is that antibody is a protein produced by B-lymphocytes that binds to a specific antigen while ranibizumab is a monoclonal antibody fragment derived from the same parent murine antibody as bevacizumab, used as an antiangiogenic.

As an adjective murine

is of, pertaining to, or characteristic of, the mouse, rat or (more generally) any mammal of the family muridae.

As a noun ranibizumab is

a monoclonal antibody fragment derived from the same parent murine antibody as bevacizumab, used as an antiangiogenic.

As nouns the difference between fragment and ranibizumab

is that fragment is fragment while ranibizumab is a monoclonal antibody fragment derived from the same parent murine antibody as bevacizumab, used as an antiangiogenic.